Short Interest in VanEck Biotech ETF (NASDAQ:BBH) Decreases By 96.4%

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 800 shares, a decline of 96.4% from the November 30th total of 22,500 shares. Based on an average daily trading volume, of 7,800 shares, the days-to-cover ratio is currently 0.1 days.

VanEck Biotech ETF Stock Down 0.6 %

Shares of VanEck Biotech ETF stock traded down $0.95 during midday trading on Friday, reaching $158.24. 9,084 shares of the company’s stock traded hands, compared to its average volume of 7,332. The company’s 50 day simple moving average is $166.22 and its 200 day simple moving average is $172.47. VanEck Biotech ETF has a 52 week low of $151.35 and a 52 week high of $183.64.

VanEck Biotech ETF Announces Dividend

The company also recently announced a dividend, which was paid on Tuesday, December 24th. Investors of record on Monday, December 23rd were issued a $1.2517 dividend. The ex-dividend date was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

Several hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC grew its holdings in shares of VanEck Biotech ETF by 10,376,390.9% during the 3rd quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock worth $202,475,000 after purchasing an additional 1,141,403 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in VanEck Biotech ETF by 5.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock worth $4,096,000 after purchasing an additional 1,334 shares during the period. Jane Street Group LLC boosted its stake in VanEck Biotech ETF by 401.7% during the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock worth $1,481,000 after buying an additional 6,684 shares in the last quarter. Atlas Capital Advisors LLC bought a new stake in VanEck Biotech ETF in the 2nd quarter valued at $960,000. Finally, Kovitz Investment Group Partners LLC raised its stake in shares of VanEck Biotech ETF by 4.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock valued at $565,000 after buying an additional 141 shares in the last quarter. 32.05% of the stock is owned by institutional investors and hedge funds.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.